Philip J Moos

List of Publications by Year in Descending Order

38 papers	1,276 citations	19 h-index	35 g-index
41 ext. papers	1,433 ext. citations	5.5 avg, IF	4.18 L-index

#	Paper	IF	Citations
38	HIV-1 provirus transcription and translation in macrophages differs from pre-integrated cDNA complexes and requires E2F transcriptional programs.. *Virulence*, **2022**, 13, 386-413	4.7	
37	Abstract OT2-19-07: A phase I/Ib trial of the CDK4/6 antagonist ribociclib (RIB) and the HDAC inhibitor belinostat (BEL) in patients with metastatic triple negative breast cancer and recurrent ovarian cancer with response prediction by genomics (CHARGE). *Cancer Research*, **2022**, 82, OT2-19-07-OT2-19-07	10.1	
36	Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. *Nature Communications*, **2021**, 12, 3039	17.4	5
35	A □one-two punch\Vtherapy strategy to target chemoresistance in estrogen receptor positive breast cancer. *Translational Oncology*, **2021**, 14, 100946	4.9	4
34	Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 16072-16082	11.5	29
33	Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model. *Cancer Cell International*, **2020**, 20, 253	6.4	8
32	Time- and dose-dependent gene expression analysis of macrophage response as a function of porosity of silica nanoparticles. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2019**, 21, 102041	6	3
31	Genotoxicity of amorphous silica nanoparticles: Status and prospects. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2019**, 16, 106-125	6	40
30	Differential gene expression patterns in vein regions susceptible versus resistant to neointimal hyperplasia. *Physiological Genomics*, **2018**, 50, 615-627	3.6	3
29	Global gene expression analysis of macrophage response induced by nonporous and porous silica nanoparticles. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2018**, 14, 533-545	6	17
28	Combating subclonal evolution of resistant cancer phenotypes. *Nature Communications*, **2017**, 8, 1231	17.4	79
27	Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. *Molecular Systems Biology*, **2016**, 12, 860	12.2	13
26	Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility. *BMC Medical Genomics*, **2015**, 8, 72	3.7	8
25	The role of thioredoxin reductase 1 in melanoma metabolism and metastasis. *Pigment Cell and Melanoma Research*, **2015**, 28, 685-95	4.5	16
24	Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer. *Molecular Oncology*, **2014**, 8, 1339-54	7.9	10
23	Toxicogenomic Evaluation of Nanomaterials **2013**, 253-260		
22	Transcriptional responses of human aortic endothelial cells to nanoconstructs used in biomedical applications. *Molecular Pharmaceutics*, **2013**, 10, 3242-52	5.6	9

21	Selenium for the prevention of cutaneous melanoma. *Nutrients*, **2013**, 5, 725-49	6.7	27
20	Major differences among chemopreventive organoselenocompounds in the sustained elevation of cytoprotective genes. *Journal of Biochemical and Molecular Toxicology*, **2012**, 26, 344-53	3.4	5
19	Responses of human cells to ZnO nanoparticles: a gene transcription study. *Metallomics*, **2011**, 3, 1199-211	4.5	74
18	Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunction. *Biochemical Pharmacology*, **2011**, 81, 211-21	6	39
17	Selenoprotein P protects cells from lipid hydroperoxides generated by 15-LOX-1. *Prostaglandins Leukotrienes and Essential Fatty Acids*, **2010**, 83, 203-10	2.8	23
16	ZnO particulate matter requires cell contact for toxicity in human colon cancer cells. *Chemical Research in Toxicology*, **2010**, 23, 733-9	4	168
15	JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1. *PLoS ONE*, **2010**, 5, e8786	3.7	13
14	Selenoprotein P reduces lipid hydroperoxides in human embryonic kidney cells following exposure to 15- hydroperoxyeicosatetraenoic acid. *FASEB Journal*, **2010**, 24, 916.7	0.9	
13	Thioredoxin reductase 1 ablation sensitizes colon cancer cells to methylseleninate-mediated cytotoxicity. *Toxicology and Applied Pharmacology*, **2009**, 241, 348-55	4.6	13
12	Selenoprotein P regulation by the glucocorticoid receptor. *BioMetals*, **2009**, 22, 995-1009	3.4	19
11	Differential gene expression in primary human skin keratinocytes and fibroblasts in response to ionizing radiation. *Radiation Research*, **2009**, 172, 82-95	3.1	40
10	Modulation of redox status in human lung cell lines by organoselenocompounds: selenazolidines, selenomethionine, and methylseleninic acid. *Toxicology in Vitro*, **2008**, 22, 1761-7	3.6	25
9	Pre- and post-initiation chemoprevention activity of 2-alkyl/aryl selenazolidine-4(R)-carboxylic acids against tobacco-derived nitrosamine (NNK)-induced lung tumors in the A/J mouse. *Chemico-Biological Interactions*, **2007**, 168, 211-20	5	15
8	Oxidation of 2-Cys-peroxiredoxins by arachidonic acid peroxide metabolites of lipoxygenases and cyclooxygenase-2. *Journal of Biological Chemistry*, **2007**, 282, 32623-9	5.4	29
7	Transient receptor potential vanilloid 1 agonists cause endoplasmic reticulum stress and cell death in human lung cells. *Journal of Pharmacology and Experimental Therapeutics*, **2007**, 321, 830-8	4.7	68
6	Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles. *Carcinogenesis*, **2006**, 27, 2538-49	4.6	89
5	Curcumin impairs tumor suppressor p53 function in colon cancer cells. *Carcinogenesis*, **2004**, 25, 1611-7	4.6	96
4	Conditional expression of 15-lipoxygenase-1 inhibits the selenoenzyme thioredoxin reductase: modulation of selenoproteins by lipoxygenase enzymes. *Journal of Biological Chemistry*, **2004**, 279, 28028-35	5.4	28

3	Impact of microarray technology in clinical oncology. *Cancer Investigation*, **2004**, 22, 312-20	2.1	23
2	Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. *Journal of Biological Chemistry*, **2003**, 278, 745-50	5.4	132
1	Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. *Journal of Biological Chemistry*, **2001**, 276, 30366-73	5.4	103